Rubicon Research started its market journey with a big splash!
The company’s shares listed on October 16, 2025, at ₹620 per share, giving investors a solid 28% premium over the IPO price of ₹485.
This debut proved that investor confidence in the pharma and healthcare sector remains strong.
👉 Source: Moneycontrol
IPO Details and Investor Response
- Price Band: ₹461 – ₹485 per share
- Total Subscription: The IPO was subscribed 48 times, showing strong retail and institutional demand.
- The response was driven by the company’s R&D strength and U.S. export exposure.
Listing Day Highlights
- NSE Listing Price: ₹620
- BSE Listing Price: ₹620.10
Both exchanges saw an impressive opening, delivering quick gains to investors.
Grey Market Premium (GMP) & Expectations
Before listing, Rubicon Research shares were trading with a GMP of nearly 30%, and the actual listing premium came close to expectations.
This shows that the company had strong market buzz before debut.
Financial Performance & Future Plans
According to Business Today, Rubicon Research’s operating income tripled, and EBITDA grew six-fold in the last three financial years (FY22–FY25).
The company plans to use IPO proceeds for loan repayment, business expansion, and acquisitions in the pharma development space.
